Information für die Wissenschaft Nr. 81 | 17. Dezember 2015
E-Rare-3 Call for Proposals 2016: Clinical Research for New Therapeutic Uses of Already Existing Molecules (Repurposing) in Rare Diseases
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) as partner of E-Rare-3 is pleased to announce the 2016 call for proposals for “Clinical Research for New Therapeutic Uses of Already Existing Molecules (Repurposing) in Rare Diseases”.
The ERA-Net “E-Rare” for research programmes on rare diseases has been extended to a third phase “E-Rare-3” (2014–2019) to further help in coordinating the research efforts of European countries in the field of rare diseases and implement the objectives of International Rare Disease Research Consortium (IRDiRC). The DFG is a funding partner among 19 other parties that have decided to open the eighth E-Rare joint transnational call (JTC 2016) for funding multinational research projects on rare diseases together with the European Commission (EC).
The aim of the call is to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project based on complementarities and sharing of expertise, with a clear translational research approach. Projects shall involve a group of rare diseases or a single rare disease following the European definition i.e. a disease affecting not more than five in 10 000 persons in the European Community, EC associated states and Canada.
The specific objective of this call is to promote clinical and pre-clinical proof of concept studies for the potential application of medicinal products that are either already marketed or having achieved a significant stage in the development process in rare indications. Thereby, two types of projects are eligible for this call. (I) Type A: Preclinical studies in a disease model for a maximum period of one year followed by the implementation of Phase 1b or Phase 2a clinical trials at the beginning of the second year of the project. (II) Type B: Milestone-driven Phase 2 clinical trials to demonstrate that the agent has the desired clinical outcome in the proposed disease population for a period up to three years.
There will be a pre-registration procedure followed by a two-stage submission/evaluation procedure for joint applications.
Pre-Registration: Coordinators of a joint transnational proposal who want to submit a project to this call shall pre-register online before 1 February 2016 at 5 p.m. GMT.
Full proposal submission stage 1: Joint full proposals (in English) must be submitted to the Joint Call Secretariat (JCS) by uploading it on the electronic submission system no later than 3 March 2016 at 5 p.m. GMT. The proposals should strictly follow the “Guidelines for applicants”. The decision on selection of applications for invitation to the second stage of submission and evaluation will be communicated by mid-June 2016.
Full proposal submission stage 2: Rebuttal/modified proposals (in English) must be submitted to the JCS in an electronic version no later than 18 July 2016 at 5 p.m. GMT. Please note that joint rebuttal/modified proposals will be accepted only from those applicants who were explicitly invited by the JCS to submit them.
Further information on how to submit pre-proposals and full proposals electronically are made available through the E-Rare website (www.erare.eu) and in the guidelines for applicants. The forms that have to be used for submission of pre-proposals and full proposals are available on the E-Rare website.
Detailed information and the guidelines for applicants are available on the E-Rare-3 website:
Link to the pre-registration and to the submission portal:
Please be aware that the eligibility requirements in form 50.01 (Guidelines for the DFG Research Grants Programme) will apply for German partners. The guideline can be found at:
Contact person at the DFG:
- Dr. Katja S. Großmann,
phone +49 228 885-2565
For general questions relating to the call or the online application system please contact the E-Rare call secretariat:
- Dr. Juliane Halftermeyer,
phone +33 1 78098022